localnews.ie

Boehringer Ingelheim and Teva refused Supreme Court appeal in inhalation capsule patent case

By Fionn Kelly

Historic decision · Decision date:

Both companies sought to appeal a Court of Appeal order on discovery of documents in the dispute over the patent behind the COPD treatment SPIRIVA.

The Supreme Court has refused both Boehringer Ingelheim Pharma GMBH and CO KG and Norton (Waterford) Ltd, trading as Teva Pharmaceuticals Ireland, leave to appeal in a patent dispute. The determination was delivered on 5 May 2016.

Boehringer holds the Irish patent for inhalation capsules, which covers SPIRIVA, a treatment for chronic obstructive pulmonary disease. Teva seeks to have the patent revoked, arguing that it lacks sufficiency or plausibility and was obvious in light of three named pieces of prior art.

The High Court had ordered five categories of discovery. The Court of Appeal upheld the first category, took a different view on the second, third and fourth, and left the timing of the fifth to the trial judge's case management. Each company then sought to appeal that order.

The Supreme Court said the orders were interlocutory and that the Court of Appeal had applied existing principles rather than new ones. It found nothing of general public importance, noting that a patent on a medicine does not of itself make a case so. A case management conference, it said, was essential.

Sources

Source: Courts Service of Ireland. Read the linked determination for the court’s exact decision.

Request a correction or removal